Study on Solanezumab’s Impact on Cognitive Decline in Mild Dementia

Overview of Alzheimer’s Disease and Antibody Treatment

Researchers in the United States are investigating whether the antibody drug solanezumab can slow cognitive decline in patients with mild dementia associated with Alzheimer’s disease. This condition is believed to stem from the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles in the brain. Mild dementia may manifest in individuals with Alzheimer’s disease, and the Aβ hypothesis posits that clearing these peptides from the brain could alleviate symptoms.

Mechanism of Solanezumab

Solanezumab is an immunoglobulin G1 monoclonal antibody designed to bind to Aβ peptides in the brain. Administered in the early stages of Alzheimer’s, it may aid in clearing Aβ plaques.

Research Design and Methodology

Researchers at Columbia University conducted a phase 3 double-blind, randomized clinical trial to evaluate the effectiveness of solanezumab in slowing the progression of Alzheimer’s disease in patients with mild dementia compared to a placebo. The study involved 2,129 participants aged 55 to 90, identified as suspected Alzheimer’s patients based on Mini-Mental State Examination (MMSE) scores and positron-emission tomography scans to detect amyloid deposits.

The participants were divided into two groups: 1,057 received 400 mg of solanezumab intravenously, while 1,072 received a placebo, with doses administered every four weeks. The trial lasted 76 weeks, and 914 (86.5%) in the solanezumab group and 908 (84.7%) in the placebo group completed the study. The findings were published in The New England Journal of Medicine, encompassing patients from 210 sites across 11 countries.

Results of the Study

The research team, led by Honig and colleagues, utilized the Alzheimer’s Disease Assessment Scale (ADAS-cog14) to measure cognitive impairment differences between the solanezumab and placebo groups compared to their baseline scores. The results indicated no significant difference in the progression of mild dementia and cognitive impairment between the two groups.

Despite the lack of significant findings, the researchers performed a secondary analysis of descriptive outcomes, noting a decline in MMSE scores that corresponded with a deterioration in cognitive health for both groups.

Adverse Events Observed

Adverse events were reported in both groups, with variations in types but no significant difference in their overall occurrence. In the solanezumab group, participants experienced issues such as difficult or painful urination and spinal osteoarthritis. Notably, adverse events in this group were not primarily linked to amyloid-related abnormalities, though the implications of this observation remain unclear.

Conclusion on Solanezumab’s Efficacy

The researchers concluded that solanezumab did not demonstrate significant positive effects in slowing cognitive decline in patients with mild dementia. This aligns with findings from two previous phase 3 clinical trials. However, some secondary analyses indicated a lesser degree of cognitive decline in individuals taking solanezumab, albeit with diminished significance in this study compared to earlier research.

Future Research Directions

The authors proposed several explanations for their findings and outlined potential avenues for future research. They suggested that merely reducing peripheral Aβ peptides might not suffice for clinically significant outcomes or that the solanezumab dosage could have been inadequate. Additionally, they considered the possibility that the disease may be self-propagating or that amyloids might not be the principal cause of Alzheimer’s. These hypotheses require further exploration, with the latter being unlikely without robust evidence from future studies.

Author Information

Written by Olajumoke Marissa Ologundudu B.Sc. (Hons)

Reference

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. New England Journal of Medicine. 2018;378(4): 321–330. doi:10.1056/nejmoa1705971